Table 4.

Hb responders at any time during treatment (all cohorts)

	Placebo or etavopivat once daily
	MAD placebo 0 mg	MAD1 300 mg	MAD2 600 mg	OL 400 mg
Wk	2	2	2	12
Number of patients, n	4	8	8	15
Maximal Hb increase, mean (range), g/dL	0.4 (0.0-0.6)	1.4 (0.4-2.4)	1.4 (0.2-3.5)	1.6 (0.8-2.8)
Hb increase >1 g/dL response on treatment, n (%)	0	7 (87.5)	4 (50.0)	11 (73.3)
Maximal Hb increase in patients with >1 g/dL response, mean (range), g/dL	NA	1.5 (1.1-2.4)	2.2 (1.5-3.5)	1.9 (1.2-2.8)

Only measurements up to EOT were included.

Hb, hemoglobin; MAD, multiple ascending dose; NA, not assessed; OL, open-label.